Mon, August 10, 2009
Fri, August 7, 2009
Thu, August 6, 2009
Wed, August 5, 2009
Tue, August 4, 2009
Mon, August 3, 2009
Sat, August 1, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009
Tue, July 28, 2009
Mon, July 27, 2009
Sat, July 25, 2009
Fri, July 24, 2009
Thu, July 23, 2009
Wed, July 22, 2009
Tue, July 21, 2009
Mon, July 20, 2009
Sun, July 19, 2009
Fri, July 17, 2009
Thu, July 16, 2009
Wed, July 15, 2009
Tue, July 14, 2009
Mon, July 13, 2009
Fri, July 10, 2009
Thu, July 9, 2009
Wed, July 8, 2009
Tue, July 7, 2009
Mon, July 6, 2009
Fri, July 3, 2009
Thu, July 2, 2009
Wed, July 1, 2009
Tue, June 30, 2009
Mon, June 29, 2009
Fri, June 26, 2009
Thu, June 25, 2009
Wed, June 24, 2009
Tue, June 23, 2009
Mon, June 22, 2009
Sun, June 21, 2009
Fri, June 19, 2009
Thu, June 18, 2009
Wed, June 17, 2009
Tue, June 16, 2009
Mon, June 15, 2009
Fri, June 12, 2009
Thu, June 11, 2009
Wed, June 10, 2009
Tue, June 9, 2009
Mon, June 8, 2009
Sun, June 7, 2009
Fri, June 5, 2009
Thu, June 4, 2009

AVI BioPharma, Inc.: AVI BioPharma, Inc. Presents at American Society of Virology Annual Meeting


//health-fitness.news-articles.net/content/2009/ .. american-society-of-virology-annual-meeting.html
Published in Health and Fitness on Tuesday, July 14th 2009 at 5:34 GMT, Last Modified on 2009-07-14 05:34:18 by Market Wire   Print publication without navigation


PORTLAND, OR--(Marketwire - July 14, 2009) - AVI BioPharma, Inc. (NASDAQ: [ AVII ]), a developer of RNA-based drugs, today announced that Dr. Fred Schnell of AVI presented at the American Society of Virology Annual Meeting which took place July 11-15 in Vancouver, B.C. The title of the presentation was "Pan-Arenavirus Antisense Therapeutic Based On PMOplus™ Chemistry." In addition to Dr. Schnell, Drs. Bestwick, Iversen and Mourich, all of AVI, coauthored the presentation.

Schnell presented results of preclinical findings using an antiviral oligomer compound that incorporates AVI's proprietary backbone chemistry (PMOplus™). The work shows that a single oligomer blocks a terminal sequence common to the eight distinct RNAs expressed by viruses from the family of hemorrhagic fever arenaviruses. Because this sequence is highly conserved among arenaviruses, a single agent might serve as a pan-arenavirus drug. Arenaviruses include Lassa fever, lymphocytic choriomeningitis, Junin and Machupo viruses, all members of the Class A bioterrorism pathogen list.

"We believe that the PMOplus™ chemistry is particularly useful for targeting potential variable or mutation prone sequences within the viral RNA," said Ryszard Kole, AVI Senior V.P. Discovery Research. "This chemistry, combined with the fact that a single agent blocks RNAs involved in several steps of the viral life cycle of a whole family of viruses, makes this approach to viral drug discovery look very promising."

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit [ www.avibio.com ].

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.


Publication Contributing Sources

Similar Health and Fitness Publications